ATE395058T1 - Verwendung von prostanoid-ep4-rezeptor- antagonisten zur behandlung von kopfschmerzen und nachweisverfahren für solche antagonisten - Google Patents

Verwendung von prostanoid-ep4-rezeptor- antagonisten zur behandlung von kopfschmerzen und nachweisverfahren für solche antagonisten

Info

Publication number
ATE395058T1
ATE395058T1 AT00912807T AT00912807T ATE395058T1 AT E395058 T1 ATE395058 T1 AT E395058T1 AT 00912807 T AT00912807 T AT 00912807T AT 00912807 T AT00912807 T AT 00912807T AT E395058 T1 ATE395058 T1 AT E395058T1
Authority
AT
Austria
Prior art keywords
antagonists
treatment
formula
prostanoid
headache
Prior art date
Application number
AT00912807T
Other languages
German (de)
English (en)
Inventor
Gordon Baxter
Robert Coleman
Nicholas Tilford
Original Assignee
Asterand Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asterand Uk Ltd filed Critical Asterand Uk Ltd
Application granted granted Critical
Publication of ATE395058T1 publication Critical patent/ATE395058T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT00912807T 2000-03-24 2000-03-24 Verwendung von prostanoid-ep4-rezeptor- antagonisten zur behandlung von kopfschmerzen und nachweisverfahren für solche antagonisten ATE395058T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2000/001138 WO2001072302A1 (en) 2000-03-24 2000-03-24 Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists

Publications (1)

Publication Number Publication Date
ATE395058T1 true ATE395058T1 (de) 2008-05-15

Family

ID=9883925

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00912807T ATE395058T1 (de) 2000-03-24 2000-03-24 Verwendung von prostanoid-ep4-rezeptor- antagonisten zur behandlung von kopfschmerzen und nachweisverfahren für solche antagonisten

Country Status (8)

Country Link
EP (1) EP1267867B1 (https=)
JP (1) JP2003528144A (https=)
AT (1) ATE395058T1 (https=)
AU (2) AU3445100A (https=)
CA (1) CA2402099C (https=)
DE (1) DE60038902D1 (https=)
DK (1) DK1267867T3 (https=)
WO (1) WO2001072302A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059742A1 (en) * 2001-10-31 2005-03-17 Jabbour Henry Nicolas Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of dysmenorrhea and menorphagia
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
JP5301469B2 (ja) * 2007-02-26 2013-09-25 メルク カナダ インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体
EP2846793A1 (en) 2012-05-09 2015-03-18 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
EA201992676A1 (ru) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов
CN110621671A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物
CN110621667A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 嘧啶衍生物
EP3625224B1 (en) 2017-05-18 2021-08-04 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives
PL3625228T3 (pl) 2017-05-18 2021-12-20 Idorsia Pharmaceuticals Ltd Pochodne pirymidyny jako modulatory receptora pge2

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2179399A1 (en) * 1993-12-20 1995-06-29 Kiyoshi Taniguchi 4,5-diaryloxazole derivatives
AUPO713297A0 (en) * 1997-06-02 1997-06-26 Fujisawa Pharmaceutical Co., Ltd. Oxazole compound
GB9720270D0 (en) * 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine
DE60012751T2 (de) * 1999-08-10 2005-01-20 Glaxo Group Ltd., Greenford Verwendung von EP 4 Rezeptorliganden zur Behandlung von neuropathischem Schmerz

Also Published As

Publication number Publication date
CA2402099A1 (en) 2001-10-04
DE60038902D1 (de) 2008-06-26
WO2001072302A1 (en) 2001-10-04
CA2402099C (en) 2011-04-26
EP1267867A1 (en) 2003-01-02
AU3445100A (en) 2001-10-08
EP1267867B1 (en) 2008-05-14
JP2003528144A (ja) 2003-09-24
AU2000234451B2 (en) 2005-09-29
DK1267867T3 (da) 2008-08-25

Similar Documents

Publication Publication Date Title
ATE144773T1 (de) Indol-derivate als 5-ht1-ähnliche antagonisten zur behandlung von migräne
ATE469892T1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
DE60217147D1 (de) Lactamderivaten zur verwendung als humane 11cby rezeptorantagonisten
DE69415614D1 (de) N-acylierte trizyklische Azaheteroringe verwendbar als Vasopressin-Antagonisten
DE60222396D1 (de) N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste
DE60038902D1 (de) Verwendung von prostanoid-ep4-rezeptor-antagonisten zur behandlung von kopfschmerzen und nachweisverfahren für solche antagonisten
ATE496620T1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
MXPA02003792A (es) Moduladores de molecula pequena de receptores de serotonina endogenos constitutivamente activados.
PE20060627A1 (es) Derivados de pirazol condensado como agonistas de los receptores cannabinoides cb1 y/o cb2
EA200400815A1 (ru) Контролируемый синтез зипразидона и его композиции
EA200200731A1 (ru) Производные фенилпиперазинила
EA200500899A1 (ru) Антагонисты аденозиндифосфатного рецептора тромбоцитов
NO20043371L (no) Kortikotropinfrigjorendefaktorreseptor-2 agonister
EA200600860A1 (ru) Производные n-тиазол-2-илбензамида
EA200000910A1 (ru) Азабициклические лиганды рецепторов 5нт1
ATE304522T1 (de) Verfahren zur hemmung von amyloidprotein aggregation und zur diagnostischen nachweis von amyloidablagerung unter verwendung von aminoindanderivaten
EA200500830A1 (ru) Производные имидазохинолина в качестве лигандов аденозиновых a3 рецепторов
PE14896A1 (es) Aminoalcanimidazoles y triazoles acilados
DE69821142D1 (de) Verwendung von prostanoiden-antagonisten zur bhandlung von primären kopfschmerzen
BG105710A (en) 5ht1 antagonists for antidepressant therapy
DE60221275D1 (de) Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma
ATE429421T1 (de) Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten
BR9916618A (pt) Compostos heterocìclicos antidepressivos
DE69819742D1 (de) Indolderivate als 5-ht1b und 5-ht1d agonisten
ATE441642T1 (de) Hydantoin derivate mit affinität für somatostatin rezeptoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties